Publications by authors named "Lotte E van der Wagen"

Background: We recently reported results of the prospective, open-label HOVON-100 trial in 334 adult patients with acute lymphoblastic leukemia (ALL) randomized to first-line treatment with or without clofarabine (CLO). No improvement of event-free survival (EFS) was observed, while a higher proportion of patients receiving CLO obtained minimal residual disease (MRD) negativity.

Aim: In order to investigate the effects of CLO in more depth, two multi-state models were developed to identify why CLO did not show a long-term survival benefit despite more MRD-negativity.

View Article and Find Full Text PDF

Background: The outcome in older patients with acute lymphoblastic leukemia (ALL) remains unsatisfactory due to high relapse and nonrelapse mortality (NRM) rates. Allogeneic stem cell transplantation (alloHSCT) as postremission therapy has an important role in reducing relapse rate, albeit its application is limited in older adult patients due to alloHSCT-related morbidity and mortality. Reduced-intensity conditioning (RIC) alloHSCT has been developed as a less toxic conditioning regimen, but comparative studies with myeloablative conditioning (MAC) are limited in patients with ALL.

View Article and Find Full Text PDF

Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment.

View Article and Find Full Text PDF
Article Synopsis
  • Clofarabine (CLO) is a treatment evaluated in a study for adults with newly diagnosed acute lymphoblastic leukemia (ALL), comparing its addition to standard induction and consolidation treatments.
  • The study involved 340 patients, revealing similar 5-year event-free survival rates (EFS) of 50% for those on CLO compared to 53% without CLO, with younger patients showing slightly better outcomes than older ones.
  • Although CLO resulted in a higher rate of minimal residual disease (MRD) negativity and complete remission (CR) rates were similar across groups, increased serious adverse events and toxicity were noted in patients treated with CLO, which may have countered potential benefits.
View Article and Find Full Text PDF

Lymphocyte numbers need to be quite tightly regulated. It is generally assumed that lymphocyte production and lifespan increase homeostatically when lymphocyte numbers are low and, vice versa, return to normal once cell numbers have normalized. This widely accepted concept is largely based on experiments in mice, but is hardly investigated in vivo in humans.

View Article and Find Full Text PDF

A 45-year-old man presented at the rheumatology outpatient department with a painful swollen hand after carpal tunnel surgery. This is a complication in approximately 2% of all patients due to complex regional pain syndrome.

View Article and Find Full Text PDF

Background: Enterococcus faecium has rapidly emerged as a nosocomial pathogen worldwide, and the majority of these isolates belong to clonal complex-17 (CC17). In Europe, CC17 isolates are usually ampicillin-resistant, but most are still vancomycin-sensitive. We aimed to study ampicillin-resistant E.

View Article and Find Full Text PDF